



OPEN LETTER

# Challenges to the performance of current HIV diagnostic assays and the need for centralized specimen archives: a review of the Consortium for the Evaluation and Performance of HIV Incidence Assays (CEPHIA) repository [version 1; peer review: 3 approved, 1 approved with reservations]

Shelley N. Facente <sup>1-3</sup>, Michael P. Busch<sup>1,2</sup>, Eduard Grebe <sup>1,2,4</sup>, Christopher D. Pilcher<sup>1</sup>, Alex Welte<sup>4</sup>, Brian Rice<sup>5</sup>, Gary Murphy <sup>6</sup>

<sup>1</sup>University of California, San Francisco, San Francisco, CA, 94110, USA

<sup>2</sup>Vitalant Research Institute (formerly Blood Systems Research Institute), San Francisco, CA, 94118, USA

<sup>3</sup>Facente Consulting, Richmond, CA, 94804, USA

<sup>4</sup>The South African DST-NRF Centre of Excellence in Epidemiological Modelling and Analysis (SACEMA), Stellenbosch University, Stellenbosch, South Africa

<sup>5</sup>London School of Hygiene and Tropical Medicine, London, UK

<sup>6</sup>Public Health England, London, UK

**v1** First published: 23 Jul 2019, 3:1511 (<https://doi.org/10.12688/gatesopenres.13048.1>)

Latest published: 23 Jul 2019, 3:1511 (<https://doi.org/10.12688/gatesopenres.13048.1>)

## Abstract

**Background:** New challenges for diagnosis of HIV infection abound, including the impact on key viral and immunological markers of HIV vaccine studies, pre-exposure prophylaxis usage and breakthrough infections, and very early initiation of anti-retroviral treatment. These challenges impact the performance of current diagnostic assays, and require suitable specimens for development and evaluation. In this article we review and describe an archive developed by the Consortium for the Evaluation and Performance of HIV Incidence Assays (CEPHIA), in order to identify the critical features required to create a centralized specimen archive to support these current and future developments.

**Review and Findings:** We review and describe the CEPHIA repository, a large, consolidated repository comprised of over 31,000 highly-selected plasma samples and other body fluid specimen types, with over 50 purposely designed specimen panels distributed to 19 groups since 2012. The CEPHIA repository provided financial return on investment, supported the standardization of HIV incidence assays, and informed guidance and standards set by the World Health Organization and UNAIDS. Unified data from extensively characterized specimens has allowed this resource to support biomarker discovery, assay optimization, and development of new strategies for estimating duration of HIV infection. Critical features of a high-value repository include 1) extensively-characterized samples, 2) high-quality clinical background data, 3) multiple collaborations facilitating ongoing sample replenishment, and 4) sustained history of high-level

## Open Peer Review

Reviewer Status

	Invited Reviewers			
	1	2	3	4
version 1 published 23 Jul 2019	 report	 report	 report	 report

- 1 **Gavin A. Cloherty**, Abbott Laboratories, Chicago, USA
- 2 **Niel T. Constantine**, University of Maryland School of Medicine, Baltimore, USA
- 3 **Bernard M. Branson** , Scientific Affairs LLC, Atlanta, USA
- 4 **Elliot P. Cowan** , Partners in Diagnostics, LLC, Rockville, USA

Any reports and responses or comments on the article can be found at the end of the article.

specimen utilization.

**Conclusion:** With strong governance and leadership, a large consolidated archive of samples from multiple studies provides investigators and assay developers with easy access to diverse samples designed to address challenges associated with HIV diagnosis, helping to enable improvements to HIV diagnostic assays and ultimately elimination of HIV. Its creation and ongoing utilization should compel funders, institutions and researchers to address and improve upon current approaches to sharing specimens.

## Keywords

HIV incidence, HIV diagnostics, repository, repositories, archived specimens, HIV

**Corresponding author:** Shelley N. Facente ([sfacente@vitalant.org](mailto:sfacente@vitalant.org))

**Author roles:** **Facente SN:** Conceptualization, Data Curation, Formal Analysis, Writing – Original Draft Preparation, Writing – Review & Editing; **Busch MP:** Conceptualization, Project Administration, Resources, Writing – Review & Editing; **Grebe E:** Data Curation, Writing – Review & Editing; **Pilcher CD:** Conceptualization, Funding Acquisition, Project Administration, Writing – Review & Editing; **Welte A:** Conceptualization, Project Administration, Supervision; **Rice B:** Conceptualization, Writing – Review & Editing; **Murphy G:** Conceptualization, Formal Analysis, Funding Acquisition, Project Administration, Writing – Original Draft Preparation, Writing – Review & Editing

**Competing interests:** No competing interests were disclosed.

**Grant information:** This work is supported by the Bill and Melinda Gates Foundation [OPP1017716, OPP1062806, OPP1115799].  
*The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.*

**Copyright:** © 2019 Facente SN *et al.* This is an open access article distributed under the terms of the [Creative Commons Attribution Licence](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

**How to cite this article:** Facente SN, Busch MP, Grebe E *et al.* **Challenges to the performance of current HIV diagnostic assays and the need for centralized specimen archives: a review of the Consortium for the Evaluation and Performance of HIV Incidence Assays (CEPHIA) repository [version 1; peer review: 3 approved, 1 approved with reservations]** Gates Open Research 2019, 3:1511 (<https://doi.org/10.12688/gatesopenres.13048.1>)

**First published:** 23 Jul 2019, 3:1511 (<https://doi.org/10.12688/gatesopenres.13048.1>)

## Introduction

Over the past three decades, archived HIV samples have allowed commercial and academic researchers to develop and evaluate multiple new HIV assays and HIV diagnostic strategies, including new approaches to measure and monitor HIV prevalence and incidence<sup>1,2</sup>. This has allowed us to achieve improved sensitivity and specificity of assays with reduced time to detect infection following HIV acquisition<sup>3–8</sup>, attain an increased range of incidence and prognostic biomarkers<sup>9–11</sup>, advance techniques for identification of diverse HIV genotypes and recombinant viruses as well as prediction of drug resistance<sup>12–18</sup>, and automate and increase throughput of diagnostic platforms<sup>19,20</sup>. Through these enhanced strategies we have not only broadened the range of potential specimen types that can be used in diagnostic and incidence testing<sup>21–23</sup>, but we have also increased the settings in which testing occurs<sup>24,25</sup> and improved estimates of infection timing<sup>26,27</sup>.

Yet despite these advancements, new challenges for diagnosis of HIV infection abound. HIV vaccine studies, increasing pre-exposure prophylaxis (PrEP) usage and PrEP breakthrough infections<sup>28–31</sup>, and very early initiation of HIV treatment have improved HIV prevention and care considerably, but require further evaluation of the impact on key viral and immunological markers of HIV, upon which existing diagnostic assays rely<sup>30,32–37</sup>. Vaccine trial participants frequently have anti-HIV positive assay results, known as vaccine-induced seropositivity (VISP), despite being HIV-negative<sup>34</sup>, and very early use of anti-retroviral treatment (ART) (including with PrEP) can have the opposite effect, leading to non-reactive antibody or ambiguous assay result combinations<sup>38</sup>. This likely occurs as a result of inhibited antibody production due to lack of sustained antigenic stimulation during a time when viral load is typically spiking<sup>39,40</sup>. Rapid reduction in viral load before antibody production is fully underway can lead to lower antibody titers and less time for antibodies to mature; assays may then detect antibodies later than expected, or not at all<sup>35</sup>. These types of new, increasingly important challenges contribute to potentially inaccurate diagnoses at the individual level and misinterpretations of data on the global stage, including inaccurate national or regional prevalence and incidence estimates, and measurement error against the WHO care cascade indicators and UNAIDS 90-90-90 targets. To reduce data misinterpretation, we require creative approaches to ongoing evaluation and enhancements of diagnostic assays and algorithms, necessitating access to suitable specimens for assay development and evaluation.

Specimen repositories previously built by the Centers for Disease Control and Prevention (CDC), National Institutes of Health (NIH), and others have supported many diagnostic developments to date. However, specimens in those repositories have often had limited distribution and no mechanism for regular replenishment, leading to a resistance of many major funders to allocate money toward sustaining those repositories or investing in additional specimen repository projects. Well-maintained repositories with substantial specimen distribution and replenishment will allow multiple current questions to be answered, and will enable us to anticipate and proactively address

future challenges to the diagnosis, monitoring, and evaluation of HIV infection.

## Review and findings

The Consortium for the Evaluation and Performance of HIV Incidence Assays (CEPHIA) was formed in 2011 with funding from the Bill and Melinda Gates Foundation; it was created in specific response to a need for cultivated specimens identified during an international Incidence Assay Critical Path Working Group, convened to review challenges and propose solutions to assay development for use in a surveillance and research context<sup>41</sup>. CEPHIA was created to support the development of existing and new HIV incidence assays, improve data analysis and interpretation of incidence assay results, and bring consensus to the field. CEPHIA is strengthened by its wide membership (see *Acknowledgements*), including close work with the World Health Organization/UNAIDS Technical Working Group on HIV Incidence Measurement and Data Use<sup>42</sup>, and a large variety of researchers and funders across the globe (see [Table 1](#) and [Table 2](#)). Importantly, the consortium was charged with setting standards and conducting independent evaluations of existing and new incidence assays, in order to remove real or perceived assay developer bias and allow direct, objective comparison of HIV incidence assays. To do this, one of CEPHIA's primary aims was to establish a repository of samples suited for these purposes.

For this paper, we review the foundation and describe the evolving development of the CEPHIA repository from late 2011 through March 2019, as a potential exemplar of a model for consolidated repository development. We calculate the estimated value of the first stage of the CEPHIA investment (CEPHIA-1, January 2011 through December 2013) by reviewing funding award documentation during that period, and summing the value of all research and programmatic uses of CEPHIA-1 samples between January 2012 and March 2019, then dividing by the total sum of the expenses related to establishment of the CEPHIA-1 repository, as well as maintenance and utilization of the repository during the initial project period. We identify critical features of a high-value repository, for consideration in future efforts to develop such a resource, and identify new types of specimens that could be included in a consolidated repository.

## Review of the CEPHIA Repository

As of March 2019, the CEPHIA repository included 94,654 aliquots of different sample types, collected from 3,383 unique individuals with 13,856 different timepoints. Most of these specimens have well-estimated durations of infection at the time of collection, demographic information, and detailed clinical information about ART history, elite control, and other characteristics.

In addition to performing its own evaluations of 11 existing HIV incidence assays, since 2012 CEPHIA has distributed over 50 purposely designed specimen panels to 19 different research and development groups. Unified data from extensively characterized, highly valuable specimens has allowed this resource to support biomarker discovery, assay optimization, and development

**Table 1. Examples of HIV assay development and related research studies supported by CEPHIA.**

Study type	Examples
<b>Focused hypothesis-driven studies</b>	<ul style="list-style-type: none"> <li>• How the gut inflammasome and specific HIV antibody subclasses change as HIV infection evolves</li> <li>• How timing of treatment initiation after HIV infection impacts kinetics of HIV reservoir seeding and opportunity for cure</li> </ul>
<b>Non-hypothesis-driven efforts to identify novel signatures of recent HIV infection</b>	<ul style="list-style-type: none"> <li>• Searches for antibodies reactive to peptoids in a large 'peptoid shape library'</li> <li>• Multiplexed assay utilizing viral and antibody markers identified and interpreted through a machine learning algorithm</li> </ul>
<b>CDC and NIH funded projects</b>	<ul style="list-style-type: none"> <li>• Examination of the factors in HIV resistance, including mutation, selection, recombination, and drift</li> <li>• Development of a single genomic assay for HIV incidence and transmitted drug resistance mutation screening</li> <li>• Independent evaluation of the Sedia Asanté™ HIV-1 Rapid Recency® Assay, currently in use by PEPFAR at international sites</li> </ul>
<b>Theoretical and toolkit innovations</b>	<ul style="list-style-type: none"> <li>• Development of a theoretical framework and web-based tool for consistent time of infection estimation based on subject-level diagnostic testing histories and the properties of diagnostic assays</li> </ul>

**Table 2. CEPHIA value generation.**

Item	Expense	Return
<b>Costs of repository</b>	<b>\$1,590,978</b>	
Specimen acquisition	\$172,000	
Specimen maintenance	\$396,091	
Panel building and shipment	\$492,100	
Database management	\$315,000	
Oversight	\$215,787	
<b>Projects made possible because of repository</b>		
NIH awardees		\$4,383,760
Gates awardees		\$3,000,000
MeSH Consortium incidence applications		\$1,300,000
CEPHIA Assay Evaluations		\$1,807,223
<b>TOTAL YIELD</b>		<b>\$10,490,983 / \$1,590,978 = \$6.59/\$1</b>

of new strategies for estimating duration of HIV infection by interpreting diagnostic histories, as shown in [Table 1](#).

The initial CEPHIA repository was built not by collecting new specimens, but by incorporating historical specimens that otherwise would have been discarded due to lack of storage and maintenance resources. Bringing together smaller, more narrowly-defined repositories added value to specimens that

may otherwise have been underutilized or even destroyed, and thus demonstrates the utility of a consolidated repository. However, CEPHIA faced many challenges in the development of its initial repository, as discussed in [Box 1](#). Other groups attempting to build new consolidated repositories will likely face these challenges, making it necessary to determine the return on investment (ROI) required to justify funding for any new repository.

**Box 1. Challenges to developing and maintaining an effective specimen repository****Finding specimens**

- Location of specimens with sufficient provenance
- Location of specimens with appropriate volumes
- Methods for obtaining specimens: Collaborate, buy, and/or negotiate
- Replenishment of the archive as specimens are utilized, while maintaining consistency across standard panels available to researchers and assay developers

**Funding**

- Securing of funding for repository development, management and maintenance, including freezer, laboratory technician time to pull and aliquot requested specimens, and data management time
- Demonstration of adequate return on investment, when the value created by disseminated panels is not always readily calculated

**Ethics**

- Marriage of the different ethical requirements of the projects that collected specimens
- Control of specimen usage when supported by commercial companies, who will later sell a product based on evaluations using specimens from the repository

**Ownership and management**

- Creation of appropriate archive management structure
- A priori decisions about the makeup of standard panels
- Determination of who should receive valuable, irreplaceable specimens
- Strategies to appropriately acknowledge the historical projects that collected these specimens

**Data**

- Standardization of the results of evaluations between assays
- Standardization of background data of specimens from many different sources
- Dissemination of results in ways that best benefit the field
- Creation and advertisement of tools to help people with their own analyses

While there are numerous benefits to the field, maintenance of a repository like CEPHIA is costly, and funding to support administrative and operational (i.e. non-research) tasks has been difficult to sustain. Specimens sitting in a freezer waiting to be distributed through a panel are often seen as a drain on resources; yet they can also be seen as a potential supply of invaluable (and sometimes irreplaceable) material, such as in the case of specimens from ART-naïve individuals with longstanding infections, increasingly difficult to come by worldwide.

It is difficult to quantify the value gained from identifying poorly performing assays so they can be removed or limited in the market; improving the understanding, confidence and application of well-performing assays; developing new research concepts and opportunities by adding value to previous studies;

or supporting external quality assessment (EQA) programs. Repository value, however, can be measured in several ways, including scientific value (measured through grants awarded, papers published, patents filed, diagnostic improvements made and new assays developed, public health application of methods, and subsequent reduction in infections), regulatory acceptance (through use of the repository to allow FDA, CE, and WHO approval of assays), financial gains (through payments from manufacturers, value of grants awarded, royalties, reduction in ancillary health costs through reduction in burden of disease), and also from a reduction in resources spent on techniques that have been shown to be ineffective. To date, our estimates of expense and funders' investments into the original plasma-only CEPHIA Repository (also known as "CEPHIA 1", funded by the Bill and Melinda Gates Foundation, OPP1017716) have had a strong value per dollar invested; when taking into account the value of projects made possible directly or indirectly by CEPHIA 1, we estimate **each dollar invested yielded approximately \$6.59 in scientific advancement** (see Table 2).

In addition to the financial yield, there were a number of other impacts of CEPHIA 1, including:

- **Standardization of HIV incidence assays, and rejection of tests that don't work.** CEPHIA was primarily initiated to conduct independent evaluations of assays in the global market that were theoretically able to detect recency of HIV infection. These evaluations were completed on 11 assays, with formal evaluations (also known as "blue books") available at the following location: <http://www.incidence-estimation.org/page/cephia-assay-evaluations>. In addition to these detailed evaluations there were a number of papers published by CEPHIA on the performance and appropriate use of available assays<sup>43-45</sup>. These evaluations and related publications have allowed major international donors to confidently use appropriate incidence assays in major surveillance activities and impact assessments, such as the Population HIV Impact Assessments (PHIAs) currently being conducted in 14 PEPFAR-supported countries<sup>46</sup>.
- **Innovative research to advance the field.** There have been 21 separate large-scale research projects funded by NIH, the Bill and Melinda Gates Foundation, and others, using CEPHIA specimens as a foundation for investigation of assays in various HIV incidence and diagnostic applications. Eleven scientific articles<sup>2,11,26,27,43,45,47-51</sup> highlighting important findings about the use (and misuse) of HIV incidence assays have been published to date with CEPHIA authorship, as a direct result of CEPHIA specimens being made available to researchers upon request.
- **Influence on guidance and standards set by the World Health Organization and UNAIDS.** Through participation on the WHO/UNAIDS Technical Working Group on HIV Incidence Measurement and Data Use, CEPHIA has had direct and ongoing influence over the information

discussed at Technical Working Group meetings and subsequently shared through various guidance documents and technical updates, available at <https://www.who.int/hiv/pub/surveillance/en/>; as one example, this influence led to a 2015 Technical Update recommending that incidence assays always be used in conjunction with viral load to appropriately calculate incidence at the population level<sup>52</sup>.

- Research informed by CEPHIA analyses and lessons learned.** In addition to specific publications, many areas of research and development have been largely informed by CEPHIA's work, including HIV cure research, antibody profiling, and infection dating. As one concrete example, to support analyses within CEPHIA it was critical to standardize estimated times since infection for each specimen timepoint. This was originally done using the conventionally-understood Fiebig staging method<sup>53</sup>. However, this was quickly found to be limiting as many specimens came from people who entered the source cohort after reaching Fiebig stage V, when antibodies had matured and the acute infection period had passed, yielding little-to-no information about infection timing. To address this limitation, CEPHIA developed a new method of infection dating now gaining traction<sup>26,27</sup>; the major benefit of the EDDI method is that it allows for a point estimate and associated credibility interval for date of first detectable infection of any person who has at least one positive and one prior negative HIV test of any kind. With the EDDI method, the tests do not have to be run on the same day and do not have to be run during the acute phase of infection in order to generate an estimated date on which a viral load assay with a 1 copy/mL limit of detection would have a 50%


chance of detecting the infection (date of first “detectable infection”). The EDDI method is flexible and a major advance over the Fiebig method given the latter's increasing limitations in this new era of HIV assays.

### Critical features of a high-value repository

We identified the following as critical features of a high-value repository: 1) extensively-characterized HIV-positive samples, including serial specimens from people with acute infection, seroconverters, and treated subjects, enabling diagnostic, pathogenesis, cure, and co-morbidity studies, 2) high-quality clinical background data, 3) multiple collaborations facilitating ongoing specimen collection and replenishment, and 4) sustained records of high-level utilization and specimen turnover, with thousands of samples shared annually. In [Figure 1](#), we describe the features of a large consolidated repository that meets these “high-value” criteria on a broad scale with centralized management.

Given the changing context of HIV diagnostics in 2019, we identified the need for new types of specimens that should be available through a consolidated repository. In order to sufficiently support the development of assays that will meet today's diagnostic challenges, we need a repository with the infrastructure to support rapid receipt, management, and dissemination of panels with the following types of specimens:

1. Large-volume, extensively-characterized HIV-positive samples, including serial specimens from seroconverters and patients with particularly early ART initiation;
2. Baseline samples from individuals starting PrEP and serial samples collected while on and after stopping PrEP, including from documented and potential PrEP-breakthrough infections;



**Figure 1. Consolidated repository concept.**

3. Chronic viremics (i.e. not virally suppressed even with longstanding infection)
4. Elite controllers (i.e. continuously virally suppressed despite not having been treated)

All specimens must have high-quality clinical background data on the patients, to ensure their utility for diagnostic, pathogenesis, cure, and co-morbidity studies. This will require multiple collaborations to facilitate specimen collection and replenishment; this is no small task considering the legal, ethical, and logistical implications of sharing large-volume specimens across the globe, for reasons other than their original intention. An effective repository should have thousands of samples shared annually, requiring extensive data management to track shipments, specimen usage, panel outputs, and high-level specimen turnover and replacement. A repository system with the capacity to independently evaluate assays that have performed well on blinded panels run in developers' laboratories (as CEPHIA has) also requires collaboration with advanced statisticians who can perform high-quality data analysis and routinely share information; our experience has shown that simply disseminating evaluation results is not sufficient, and hands-on technical assistance strategies are required in order to support clinicians and researchers in understanding what the results really mean.

## Discussion

Despite having a reputation as expensive white elephants, our review highlights that specimen repositories can play an invaluable role in the development, optimization, and validation of diagnostic assays. The CEPHIA repository demonstrates how a targeted approach can identify and capture a wealth of specimens and associated information that already exists, and *gain* value by being drawn together for a different purpose. Developing the archive required overcoming a number of significant challenges, and despite its demonstrated value given the financial investment, lack of consistent funding threatens the existence of the CEPHIA repository and the collaborative team that supports its use. To successfully develop and sustain a consolidated repository model, we must think in new ways about our scientific work as part of a collective whole. To this end, through this review we have identified critical features of a high-value repository, leading to the following proposals:

1. **Funders of studies should be more explicit in their guidance to awardees about requirements to release specimens utilized for the study as soon as any primary or secondary aims of the initial study are complete**, and this should be completed within a defined timeframe. 'Ownership' of specimens collected through studies is a significant hurdle to overcome in the development of a consolidated repository. Understandably, individuals typically do not want to release specimens held in their archives without guarantees that the work performed on them is going to be valuable, and institutions worry about yielding control of specimens under their purview. Indeed, specimens in a consolidated repository may be used in ways that diverge from the expertise of the researchers who were instrumental in their collection, often leading to further reluctance to collaborate. Funders should also look across the repertoire of studies they fund, to help identify where specimens may be available and how specimens collected from one study may be beneficial to others.
2. **In developing ethical approval for studies, more emphasis should be placed on ensuring that specimens collected can be used for other, perhaps currently unknown, purposes.** This may mean setting a period of time for the study after which anonymization of specimens is routinely conducted so they may be broadly shared. It will also likely require that further explanation of the potential uses of specimens be given to study participants at the time of consent.
3. **Journals should come to some general consensus about the best mechanisms for acknowledging researchers who contributed specimens that were later used for a secondary study.** In a large repository with rapid turnover of specimens, inclusion of all researchers contributing specimens into the authorship list of any subsequent papers is likely impractical. Yet especially in academia, where a publication record is typically a major factor in continued employment and promotion, rights to authorship is critical currency when determining whether specimens should be shared with a repository system for future use. Recognition of the hard work that went into specimen acquisition and initial maintenance – as well as incentivization for collegial relationships between researchers – would be an important way to ensure successful construction of a consolidated repository.
4. **Major funders should ensure that studies collect as much ancillary data around the work they do as possible without infringing on the rights of study participants.** While most researchers work to minimize and streamline data collection to improve participant enrollment rates (i.e. not requiring participants to disclose full medical histories), there are many simple factors of study protocol or process that could help with the effective use of specimens for subsequent analyses. One clear example of this is the type of assay used to confirm an infection, which due to different sensitivities and specificities may, over time, affect how an assay result may be interpreted or how a specimen may be categorized.
5. **Leadership of a consolidated repository should be supported by the endorsement of major funders and normative agencies.** With international, influential commitments to the development and use of a major repository to address upcoming challenges to HIV diagnostics, the ease of securing appropriate specimens will dramatically increase. The repository should be open internationally, with its use based on scientific

need, with clear systems and guidelines for specimen access. Further, management of the repository should not just include physically obtaining, storing, and shipping specimens, but should also involve skilled support for data analysis, to help guide users in proper application of the specimens and their associated information. Standards should be set for commercial use of specimens, such that for-profit development is allowed with an appropriate exchange of funding that helps the repository be sustained for the future.

6. **Repository owners should attempt to develop an ROI methodology.** To assist with sustainable funding for useful consolidated repositories, a mechanism to fairly track investments, expenses, and returns is imperative. Such a system will help potential funders see the benefits of their investments in these projects, and should also include metrics to determine whether a repository should continue or whether the ROI has fallen to a point such that future funding should cease and specimens should be disseminated for storage in other more productive settings.

In summary, with strong governance and leadership, a consolidated repository provides academic investigators and commercial assay developers with easy access to diverse specimens through a large consolidated archive of specimens from multiple studies, helping to advance improvements to HIV diagnostic assays and ultimately elimination of HIV. An international commitment to the development and/or maintenance of this type of resource is imperative, for the field of HIV diagnostics and incidence measurement to continue to move forward and face new challenges.

#### Data availability

No data is associated with this article.

#### Grant information

This work is supported by the Bill and Melinda Gates Foundation [OPP1017716, OPP1062806, OPP1115799].

*The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.*

#### Acknowledgements

The Consortium for the Evaluation and Performance of HIV Incidence Assays (CEPHIA) comprises: Alex Welte, Joseph Sempa, formerly: David Matten, Hilmarié Brand, Trust Chibawara (South African Centre for Epidemiological Modelling and Analysis, Stellenbosch University); Gary Murphy, Jake Hall, formerly: Elaine Mckinney (Public Health England); Michael P. Busch, Eduard Grebe, Shelley Facente, Dylan Hampton, Sheila Keating, formerly: Mila Lebedeva (Vitalant Research Institute, formerly Blood Systems Research Institute); Christopher D. Pilcher, Kara Marson (University of California San Francisco); Reshma Kassanjee (University of Cape Town); Oliver Laeyendecker, Thomas Quinn, David Burns (National Institutes of Health); Susan Little (University of California San Diego); Anita Sands (World Health Organization); Tim Hallett (Imperial College London); S. Michele Owen, Bharat Parekh, Connie Sexton (Centers for Disease Control and Prevention); Matthew Price, Anatoli Kamali (International AIDS Vaccine Initiative); Lisa Loeb (The Options Study – University of California San Francisco); Jeffrey Martin, Steven G Deeks, Rebecca Hoh (The SCOPE Study – University of California San Francisco); Zelinda Bartolomei, Natalia Cerqueira (The AMPLIAR Cohort – University of São Paulo); Breno Santos, Kellin Zabtowski, Rita de Cassia Alves Lira (The AMPLIAR Cohort – Grupo Hospital Conceição); Rosa Dea Sperhake, Leonardo R Motta, Machline Paganella (The AMPLIAR Cohort – Universidade Caxias Do Sul); Esper Kallas, Helena Tomiyama, Claudia Tomiyama, Priscilla Costa, Maria A Nunes, Gisele Reis, Mariana M Sauer, Natalia Cerqueira, Zelinda Nakagawa, Lilian Ferrari, Ana P Amaral, Karine Milani (The São Paulo Cohort – University of São Paulo, Brazil); Salim S Abdool Karim, Quarraisha Abdool Karim, Thumbi Ndungu, Nelisile Majola, Natasha Samsunder (CAPRISA, University of Kwazulu-Natal); Denise Naniche (The GAMA Study – Barcelona Centre for International Health Research); Inácio Mandomando, Eusebio V Macete (The GAMA Study – Fundacao Manhica); Jorge Sanchez, Javier Lama (SABES Cohort – Asociación Civil Impacta Salud y Educación (IMPACTA)); Ann Duerr (The Fred Hutchinson Cancer Research Center); Maria R Capobianchi (National Institute for Infectious Diseases “L. Spallanzani”, Rome); Barbara Suligoj (Istituto Superiore di Sanità, Rome); Susan Stramer (American Red Cross); Phillip Williamson (Creative Testing Solutions / Vitalant Research Institute); Marion Vermeulen (South African National Blood Service); and Ester Sabino (Hemocentro do São Paulo).

#### References

- Busch MP, Pilcher CD, Mastro TD, *et al.*: **Beyond detuning: 10 years of progress and new challenges in the development and application of assays for HIV incidence estimation.** *AIDS*. 2010; **24**(18): 2763–71. [PubMed Abstract](#) | [Publisher Full Text](#)
- Murphy G, Pilcher CD, Keating SM, *et al.*: **Moving towards a reliable HIV incidence test - current status, resources available, future directions and challenges ahead.** *Epidemiol Infect*. 2017; **145**(5): 925–941. [PubMed Abstract](#) | [Publisher Full Text](#)
- Delaney KP, Hanson DL, Masciotra S, *et al.*: **Time Until Emergence of HIV Test Reactivity Following Infection With HIV-1: Implications for Interpreting Test Results and Retesting After Exposure.** *Clin Infect Dis*. 2017; **64**(1): 53–9. [PubMed Abstract](#) | [Publisher Full Text](#)
- Delaney KP, Wesolowski LG, Owen SM: **The Evolution of HIV Testing Continues.** *Sex Transm Dis*. 2017; **44**(12): 747–9. [PubMed Abstract](#) | [Publisher Full Text](#)
- Perry KR, Ramskill S, Eglin RP, *et al.*: **Improvement in the performance of HIV screening kits.** *Transfus Med*. 2008; **18**(4): 228–40. [PubMed Abstract](#) | [Publisher Full Text](#)
- Qiu X, Sokoll L, Yip P, *et al.*: **Comparative evaluation of three FDA-approved HIV Ag/Ab combination tests using a genetically diverse HIV panel and diagnostic**

- specimens. *J Clin Virol.* 2017; **92**: 62–8.  
[PubMed Abstract](#) | [Publisher Full Text](#)
7. Constantine NT, Zink H: **HIV testing technologies after two decades of evolution.** *Indian J Med Res.* 2005; **121**(4): 519–38.  
[PubMed Abstract](#)
  8. Constantine NT, Zekeng L, Sangare AK, *et al.*: **Diagnostic challenges for rapid human immunodeficiency virus assays. Performance using HIV-1 group O, HIV-1 group M, and HIV-2 samples.** *J Hum Virol.* 1997; **1**(1): 45–51.  
[PubMed Abstract](#)
  9. Su B, Fu Y, Liu Y, *et al.*: **Potential Application of MicroRNA Profiling to the Diagnosis and Prognosis of HIV-1 Infection.** *Front Microbiol.* 2018; **9**: 3185.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
  10. Grebe E, Welte A, Johnson LF, *et al.*: **Population-level HIV incidence estimates using a combination of synthetic cohort and recency biomarker approaches in KwaZulu-Natal, South Africa.** *PLoS One.* 2018; **13**(9): e0203638.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
  11. Seaton KE, Vandergrift NA, Deal AW, *et al.*: **Computational analysis of antibody dynamics identifies recent HIV-1 infection.** *JCI Insight.* 2017; **2**(24): pii: 94355.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
  12. Zhang G, DeVos J, Medina-Moreno S, *et al.*: **Utilization of dried blood spot specimens can expedite nationwide surveillance of HIV drug resistance in resource-limited settings.** *PLoS One.* 2018; **13**(9): e0203296.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
  13. Inzaule SC, Hamers RL, Paredes R, *et al.*: **The Evolving Landscape of HIV Drug Resistance Diagnostics for Expanding Testing in Resource-Limited Settings.** *AIDS Rev.* 2017; **19**(4): 219–30.  
[PubMed Abstract](#)
  14. Dessilly G, Goeminne L, Vandenbroucke AT, *et al.*: **First evaluation of the Next-Generation Sequencing platform for the detection of HIV-1 drug resistance mutations in Belgium.** *PLoS One.* 2018; **13**(12): e0209561.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
  15. Global HIV Strategic Information Working Group: **Recent Infection Testing Algorithm Technical Update: Applications for HIV surveillance and programme monitoring.** Geneva; 2018.  
[Reference Source](#)
  16. External Quality Assurance Program Oversight Laboratory (EQAPOL): **Let the EQAPOL Viral Diversity Program Enhance Your Research! Duke Human Vaccine Institute.** 2017.
  17. Sanchez AM, DeMarco CT, Hora B, *et al.*: **Development of a contemporary globally diverse HIV viral panel by the EQAPOL program.** *J Immunol Methods.* 2014; **409**: 117–30.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
  18. Hora B, Keating SM, Chen Y, *et al.*: **Genetic Characterization of a Panel of Diverse HIV-1 Isolates at Seven International Sites.** *PLoS One.* 2016; **11**(6): e0157340.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
  19. Jani IV, Sabatier J, Vubil A, *et al.*: **Evaluation of a high-throughput diagnostic system for detection of HIV-1 in dried blood spot samples from infants in Mozambique.** *J Clin Microbiol.* 2012; **50**(4): 1458–60.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
  20. Mitchell EO, Stewart G, Bajzik O, *et al.*: **Performance comparison of the 4th generation Bio-Rad Laboratories GS HIV Combo Ag/Ab EIA on the EVOLIS™ automated system versus Abbott ARCHITECT HIV Ag/Ab Combo, Ortho Anti-HIV 1+2 EIA on Vitros ECI and Siemens HIV-1/O/2 enhanced on Advia Centaur.** *J Clin Virol.* 2013; **58** Suppl 1: e79–84.  
[PubMed Abstract](#) | [Publisher Full Text](#)
  21. Luo W, Masciotra S, Delaney KP, *et al.*: **Comparison of HIV oral fluid and plasma antibody results during early infection in a longitudinal Nigerian cohort.** *J Clin Virol.* 2013; **58** Suppl 1: e113–8.  
[PubMed Abstract](#) | [Publisher Full Text](#)
  22. Takano M, Iwahashi K, Satoh I, *et al.*: **Assessment of HIV prevalence among MSM in Tokyo using self-collected dried blood spots delivered through the postal service.** *BMC Infect Dis.* 2018; **18**(1): 627.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
  23. van Schalkwyk C, Maritz J, van Zyl GU, *et al.*: **Pooled PCR testing of dried blood spots for infant HIV diagnosis is cost efficient and accurate.** *BMC Infect Dis.* 2019; **19**(1): 136.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
  24. Kelvin EA, George G, Kinyanjui S, *et al.*: **Announcing the availability of oral HIV self-test kits via text message to increase HIV testing among hard-to-reach truckers in Kenya: a randomized controlled trial.** *BMC Public Health.* 2019; **19**(1): 7.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
  25. Page M, Atabani SF, Wood M, *et al.*: **Dried blood spot and mini-tube blood sample collection kits for postal HIV testing services: a comparative review of successes in a real-world setting.** *Sex Transm Infect.* 2019; **95**(1): 43–5.  
[PubMed Abstract](#) | [Publisher Full Text](#)
  26. Grebe E, Facente SN, Bingham J, *et al.*: **Interpreting HIV Diagnostic Histories into Infection Time Estimates: Analytical Framework and Online Tool.** *bioRxiv.* (article under review). 2018.  
[Publisher Full Text](#)
  27. Pilcher CD, Porco TC, Facente SN, *et al.*: **A generalizable method for estimating duration of HIV infections using clinical testing history and HIV test results.** *AIDS.* 2019; **33**(7): 1231–40.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
  28. Baeten JM, Donnell D, Ndase P, *et al.*: **Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.** *N Engl J Med.* 2012; **367**(5): 399–410.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
  29. Desai M, Field N, Grant R, *et al.*: **Recent advances in pre-exposure prophylaxis for HIV.** *BMJ.* 2017; **359**: j5011.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
  30. Smith DK, Switzer WM, Peters P, *et al.*: **A Strategy for PrEP Clinicians to Manage Ambiguous HIV Test Results During Follow-up Visits.** *Open Forum Infect Dis.* 2018; **5**(8): ofy180.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
  31. U.S. Department of Health and Human Services: **Ending the HIV Epidemic: A Plan for America.** Washington, D.C., 2019.  
[Reference Source](#)
  32. Veldsman KA, Maritz J, Isaacs S, *et al.*: **Rapid decline of HIV-1 DNA and RNA in infants starting very early antiretroviral therapy may pose a diagnostic challenge.** *AIDS.* 2018; **32**(5): 629–34.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
  33. Boyd MA, Boffito M, Castagna A, *et al.*: **Rapid initiation of antiretroviral therapy at HIV diagnosis: definition, process, knowledge gaps.** *HIV Med.* 2019; **20**(Suppl 1): 3–11.  
[PubMed Abstract](#) | [Publisher Full Text](#)
  34. VISR Working Group of Global HIV Vaccine Enterprise, Voronin Y, Zinszner H, *et al.*: **HIV vaccine-induced sero-reactivity: a challenge for trial participants, researchers, and physicians.** *Vaccine.* 2015; **33**(10): 1243–9.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
  35. Murphy G, Brown CS, Bradshaw D, *et al.*: **Atypical HIV test results when PrEP is prevalent - a need for vigilance in the laboratory.** *Microbiol Today.* 2018; **164**–7.  
[Reference Source](#)
  36. Donnell D, Ramos E, Celum C, *et al.*: **The effect of oral preexposure prophylaxis on the progression of HIV-1 seroconversion.** *AIDS.* 2017; **31**(14): 2007–16.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
  37. Henrich TJ, Hatano H, Bacon O, *et al.*: **HIV-1 persistence following extremely early initiation of antiretroviral therapy (ART) during acute HIV-1 infection: An observational study.** *PLoS Med.* 2017; **14**(11): e1002417.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
  38. Rutstein SE, Ananworanich J, Fidler S, *et al.*: **Clinical and public health implications of acute and early HIV detection and treatment: a scoping review.** *J Int AIDS Soc.* 2017; **20**(1): 21579.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
  39. Jagodzinski LL, Manak MM, Hack HR, *et al.*: **Impact of Early Antiretroviral Therapy on Detection of Cell-Associated HIV-1 Nucleic Acid in Blood by the Roche Cobas TaqMan Test.** *J Clin Microbiol.* 2019; **57**(5): pii: e01922-18.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
  40. Keating SM, Pilcher CD, Busch MP: **Editorial Commentary: Timing Is Everything: Shortcomings of Current HIV Diagnostics in the Early Treatment Era.** *Clin Infect Dis.* 2016; **63**(4): 562–4.  
[PubMed Abstract](#) | [Publisher Full Text](#)
  41. Incidence Assay Critical Path Working Group: **More and better information to tackle HIV epidemics: towards improved HIV incidence assays.** *PLoS Med.* 2011; **8**(6): e1001045.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
  42. World Health Organization: **Meeting Report: WHO Working Group on HIV Incidence Measurement and Data Use.** Boston: World Health Organization; 2018.  
[Reference Source](#)
  43. Kassinjee R, Pilcher CD, Keating SM, *et al.*: **Independent assessment of candidate HIV incidence assays on specimens in the CEPHIA repository.** *AIDS.* 2014; **28**(16): 2439–49.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
  44. Sempa J, Welte A, Busch MP, *et al.*: **Performance of the Maxim and Sedia Limiting Antigen Avidity assays for population-level HIV incidence surveillance.** *PLoS One.* (in press).
  45. Grebe E, Welte A, Hall J, *et al.*: **Infection Staging and Incidence Surveillance Applications of High Dynamic Range Diagnostic Immuno-Assay Platforms.** *J Acquir Immune Defic Syndr.* 2017; **76**(5): 547–55.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
  46. ICAP: **PHIA Project Countries.** New York, NY: Columbia University; 2019.  
[Reference Source](#)
  47. Kassinjee R, Pilcher CD, Busch MP, *et al.*: **Viral load criteria and threshold optimization to improve HIV incidence assay characteristics.** *AIDS.* 2016; **30**(15): 2361–71.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
  48. Keating SM, Kassinjee R, Lebedeva M, *et al.*: **Performance of the Bio-Rad Geenius HIV1/2 Supplemental Assay in Detecting “Recent” HIV Infection and Calculating Population Incidence.** *J Acquir Immune Defic Syndr.* 2016; **73**(5): 581–8.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
  49. Schlusser KE, Pilcher C, Kallas EG, *et al.*: **Comparison of cross-sectional HIV incidence assay results from dried blood spots and plasma.** *PLoS One.* 2017; **12**(2): e0172283.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)

50. Keating SM, Pilcher CD, Jain V, *et al.*: **HIV Antibody Level as a Marker of HIV Persistence and Low-Level Viral Replication.** *J Infect Dis.* 2017; **216**(1): 72–81.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
51. Hassan J, Moran J, Murphy G, *et al.*: **Discrimination between recent and non-recent HIV infections using routine diagnostic serological assays.** *Med Microbiol Immunol.* 2019.  
[PubMed Abstract](#) | [Publisher Full Text](#)
52. Joint United Nations Programme on HIV/AIDS (UNAIDS), World Health Organization (WHO): **Technical Update on HIV Incidence Assays for Surveillance and Monitoring Purposes.** Geneva; 2015.  
[Reference Source](#)
53. Fiebig EW, Wright DJ, Rawal BD, *et al.*: **Dynamics of HIV viremia and antibody seroconversion in plasma donors: implications for diagnosis and staging of primary HIV infection.** *AIDS.* 2003; **17**(13): 1871–9.  
[PubMed Abstract](#) | [Publisher Full Text](#)

## Open Peer Review

Current Peer Review Status:



### Version 1

Reviewer Report 30 August 2019

<https://doi.org/10.21956/gatesopenres.14170.r27669>

© 2019 Cowan E. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution Licence](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.



**Elliot P. Cowan** 

Partners in Diagnostics, LLC, Rockville, MD, USA

This Open Letter describes the creation of a specimen repository to advance the development of HIV diagnostic assays. It makes its points clearly, identifying not only the value of the CEPHIA repository but also the challenges encountered in assembling it. I see the assembly of the repository a remarkable achievement that should be a model for the generation of other repositories for other infectious agents and diseases. I found the proposals at the end of the Open Letter to be especially provocative (in its most positive sense), presenting clear paths forward that will undoubtedly go a long way in getting the most out of the repository. Some comments to consider:

The Letter correctly sees value in the repository for, “regulatory acceptance (through use of the repository to allow FDA, CE, and WHO approval of assays).” It will be important to understand from those bodies what they expect for that acceptance. This especially includes ethical issues (which the authors recognize as important to address).

The repository will be an important tool in product development by IVD manufacturers. How do the authors, or do they, envision making repository samples available to product developers?

Understandably, the CEPHIA repository took several years to assemble and continues to be a work in progress. I would like the authors to comment on how they can apply their experience to assembling a repository when there is a public health emergency, in which assays are desperately needed and critical specimens for test development and validation are extremely difficult to source.

**Is the rationale for the Open Letter provided in sufficient detail?**

Yes

**Does the article adequately reference differing views and opinions?**

Yes

**Are all factual statements correct, and are statements and arguments made adequately supported by citations?**

Yes

**Is the Open Letter written in accessible language?**

Yes

**Where applicable, are recommendations and next steps explained clearly for others to follow?**

Yes

**Competing Interests:** I assist IVD manufacturers in addressing regulatory issues encountered by their products.

**Reviewer Expertise:** IVD development, and assessment of quality and compliance with regulatory requirements; global health

**I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.**

Reviewer Report 22 August 2019

<https://doi.org/10.21956/gatesopenres.14170.r27584>

© 2019 Branson B. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution Licence](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.



**Bernard M. Branson** 

Scientific Affairs LLC, Atlanta, GA, USA

This open letter describes the CEPHIA repository and its role in development of evaluation of HIV incidence assays, and proposes it serve as a “potential exemplar for consolidated repository development.” The authors note (Review and Findings) that “CEPHIA was created to support the development of existing and new HIV incidence assays, improve data analysis and interpretation of incidence assay results, and bring consensus to the field,” and note (Discussion) that “lack of consistent funding threatens the existence of the CEPHIA repository and the collaborative team that supports its use.” I have significant reservations about this letter from my eminent colleagues, and I provide extensive comment because of my respect for the hard work these colleagues have done.

The prospect of using a serologic assay to directly measure (or estimate) HIV incidence from cross-sectional specimen collection first showed promise using a somewhat primitive modified ELISA in 1998 (Janssen *et al.*, 1998<sup>2</sup>). Subsequent assays were developed to address the shortcomings identified with each later iteration of assays (Busch *et al.*, 2010<sup>3</sup>), but, as specified in several of the authors’ citations, no single assay method can precisely estimate incidence; WHO guidance stipulates that assay-based estimation is not absolute (World Health Organization, 2018<sup>4</sup>); and other studies by these same authors demonstrate that assay-based incidence estimates with the same specimens differ depending on the assay, specimen type, and context (Schlusser *et al.*, 2017<sup>5</sup> and Sempa *et al.*, 2019<sup>6</sup>). These cause me concern about the implications of the recent proposed deployment of the rapid POC “recency” assay (authors’ citation 46) reminiscent of the premature distribution of the BED assay.

[https://apps.who.int/iris/bitstream/handle/10665/233008/WER8104\\_40-40.PDF?sequence=1&isAllowed=1](https://apps.who.int/iris/bitstream/handle/10665/233008/WER8104_40-40.PDF?sequence=1&isAllowed=1)

At CEPHIA's inception, acquisition of specimens collected from other studies was anticipated as a shortcut, quicker and less expensive than a purposefully designed prospective specimen collection from an observational cohort. However, the best sources for CEPHIA specimens were other cohorts (e.g., Zvitambo, CHAVI) (Gonese *et al.*, 2019<sup>7</sup> and Seaton *et al.*, 2017<sup>8</sup>) with limited specimen volumes for which there are other competing research interests. The CEPHIA panel suffers from several shortcomings in that many specimen sets are based on estimated (not observed) dates of infection, and the panel constituents do not allow direct comparison of assay-based incidence results to observed incidence. Finally, the CEPHIA panel will also not help address the pressing new challenges for diagnosis in persons taking PrEP, PEP, or early ART, and will not allow for examination of new molecular methods or POC specimen types, for which better specimen sources are available (i.e., SEARCH studies, ClinicalTrials.gov NCT00796146 and NCT00796263, underway since 2008) (Ananworanich *et al.*, 2013<sup>9</sup> and de Souza *et al.*, 2016<sup>10</sup>).

After 20 years' effort, serologic incidence estimation has yet to achieve proof of concept. All survey results require extensive mathematical manipulation, and reinterpretations are frequent. All assay methods evaluated to date extensively misclassify persons on ART, which inflates incidence estimates. CDC's domestic surveillance has abandoned serologic incidence assays in favor of a CD4 depletion model (Hall *et al.*, 2017<sup>11</sup>).

The authors do not indicate why they believe collection of specimens and maintenance of a repository should not be a government responsibility (e.g., DoD HIV specimen repository (Perdue *et al.*, 2015<sup>12</sup>), Lyme repository (Molins *et al.*, 2014<sup>13</sup>), CHAVI, ACTG, HPTN, and MACS HIV specimen repositories), nor why a prospective plan is not designed and implemented, such as the NHLBI national blueprint for 21st century data and specimen collection and observational cohort studies (Konkle and Recht, 2019<sup>14</sup>).

Finally, the authors' estimates of the repository appear to neglect the fixed costs associated with development, maintenance, and monitoring of a repository (Baird and Gunter, 2016<sup>15</sup>), and I am reluctant to equate grants received (including, I expect, some by these authors) as ROI. If ROI justified incidence assays, industry would underwrite the specimen repositories.

## References

1. Incidence Assay Critical Path Working Group: More and better information to tackle HIV epidemics: towards improved HIV incidence assays. *PLoS Med.* 2011; **8** (6): e1001045 [PubMed Abstract](#) | [Publisher Full Text](#)
2. Janssen RS, Satten GA, Stramer SL, Rawal BD, O'Brien TR, Weiblen BJ, Hecht FM, Jack N, Cleghorn FR, Kahn JO, Chesney MA, Busch MP: New testing strategy to detect early HIV-1 infection for use in incidence estimates and for clinical and prevention purposes. *JAMA.* 1998; **280** (1): 42-8 [PubMed Abstract](#) | [Publisher Full Text](#)
3. Busch MP, Pilcher CD, Mastro TD, Kaldor J, Vercauteren G, Rodriguez W, Rousseau C, Rehle TM, Welte A, Averill MD, Garcia Calleja JM, WHO Working Group on HIV Incidence Assays: Beyond detuning: 10 years of progress and new challenges in the development and application of assays for HIV incidence estimation. *AIDS.* 2010; **24** (18): 2763-71 [PubMed Abstract](#) | [Publisher Full Text](#)
4. World Health Organization: Meeting Report: WHO Working Group on HIV Incidence Measurement and Data Use. 2018. [Reference Source](#)
5. Schlusser KE, Pilcher C, Kallas EG, Santos BR, Deeks SG, Facente S, Keating SM, Busch MP,

- Murphy G, Welte A, Quinn T, Eshleman SH, Laeyendecker O: Comparison of cross-sectional HIV incidence assay results from dried blood spots and plasma. *PLoS One*. 2017; **12** (2): e0172283 [PubMed Abstract](#) | [Publisher Full Text](#)
6. Sempa JB, Welte A, Busch MP, Hall J, Hampton D, Facente SN, Keating SM, Marson K, Parkin N, Pilcher CD, Murphy G, Grebe E, Consortium for the Evaluation and Performance of HIV Incidence Assays CEPHIA: Performance comparison of the Maxim and Sedia Limiting Antigen Avidity assays for HIV incidence surveillance. *PLoS One*. 2019; **14** (7): e0220345 [PubMed Abstract](#) | [Publisher Full Text](#)
7. Gonese E, Kilmarx PH, van Schalkwyk C, Grebe E, Mutasa K, Ntozini R, Parekh B, Dobbs T, Duong Pottinger Y, Masciotra S, Owen M, Nachega JB, van Zyl G, Hargrove JW: Evaluation of the Performance of Three Biomarker Assays for Recent HIV Infection Using a Well-Characterized HIV-1 Subtype C Incidence Cohort. *AIDS Res Hum Retroviruses*. 2019; **35** (7): 615-627 [PubMed Abstract](#) | [Publisher Full Text](#)
8. Seaton K, Vandergrift N, Deal A, Rountree W, Bainbridge J, Grebe E, Anderson D, Sawant S, Shen X, Yates N, Denny T, Liao H, Haynes B, Robb M, Parkin N, Santos B, Garrett N, Price M, Naniche D, Duerr A, Keating S, Hampton D, Facente S, Marson K, Welte A, Pilcher C, Cohen M, Tomaras G: Computational analysis of antibody dynamics identifies recent HIV-1 infection. *JCI Insight*. 2017; **2** (24). [Publisher Full Text](#)
9. Ananworanich J, Fletcher JL, Pinyakorn S, van Griensven F, Vandergeeten C, Schuetz A, Pankam T, Trichavaroj R, Akapirat S, Chomchey N, Phanuphak P, Chomont N, Michael NL, Kim JH, de Souza M, RV254/SEARCH 010 Study Group: A novel acute HIV infection staging system based on 4th generation immunoassay. *Retrovirology*. 2013; **10**: 56 [PubMed Abstract](#) | [Publisher Full Text](#)
10. de Souza M, Pinyakorn S, Akapirat S, Pattanachaiwit S, Fletcher J, Chomchey N, Kroon E, Ubolyam S, Michael N, Robb M, Phanuphak P, Kim J, Phanuphak N, Ananworanich J: Initiation of Antiretroviral Therapy During Acute HIV-1 Infection Leads to a High Rate of Nonreactive HIV Serology. *Clinical Infectious Diseases*. 2016; **63** (4): 555-561 [Publisher Full Text](#)
11. Hall HI, Song R, Tang T, An Q, Prejean J, Dietz P, Hernandez AL, Green T, Harris N, McCray E, Mermin J: HIV Trends in the United States: Diagnoses and Estimated Incidence. *JMIR Public Health Surveill*. 2017; **3** (1): e8 [PubMed Abstract](#) | [Publisher Full Text](#)
12. Perdue CL, Eick-Cost AA, Rubertone MV: A Brief Description of the Operation of the DoD Serum Repository. *Mil Med*. 2015; **180** (10 Suppl): 10-2 [PubMed Abstract](#) | [Publisher Full Text](#)
13. Molins CR, Sexton C, Young JW, Ashton LV, Pappert R, Beard CB, Schriefer ME: Collection and characterization of samples for establishment of a serum repository for lyme disease diagnostic test development and evaluation. *J Clin Microbiol*. 2014; **52** (10): 3755-62 [PubMed Abstract](#) | [Publisher Full Text](#)
14. Konkle BA, Recht M, members of Working Group 2, the NHLBI State of the Science Workshop on factor VIII inhibitors: Generating a national blueprint for future research: The national blueprint for 21st century data and specimen collection and observational cohort studies: NHLBI State of the Science Workshop on factor VIII inhibitors. *Haemophilia*. 2019; **25** (4): 590-594 [PubMed Abstract](#) | [Publisher Full Text](#)
15. Baird PM, Gunter EW: Repository Planning, Design, and Engineering: Part II-Equipment and Costing. *Biopreserv Biobank*. 2016; **14** (4): 338-49 [PubMed Abstract](#) | [Publisher Full Text](#)

**Is the rationale for the Open Letter provided in sufficient detail?**

Partly

**Does the article adequately reference differing views and opinions?**

No

**Are all factual statements correct, and are statements and arguments made adequately supported by citations?**

Partly

**Is the Open Letter written in accessible language?**

Yes

**Where applicable, are recommendations and next steps explained clearly for others to follow?**

Yes

**Competing Interests:** Full disclosure: I was employed at CDC until 2014, at one time responsible for the identification, acquisition, and tracking of specimens for evaluating incidence assays, and for the application and use of some assays as part of the US HIV Surveillance System's incidence estimates. I was also part of the international Incidence Assay Critical Paths Working Group in 2011, during which CEPHIA was conceived (reference 1). I confirm that this hasn't affected my ability to write an objective review of the article.

**Reviewer Expertise:** HIV diagnostics and epidemiology; formerly, Associate Director for HIV Laboratory Diagnostics at CDC

**I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.**

Reviewer Report 21 August 2019

<https://doi.org/10.21956/gatesopenres.14170.r27583>

© 2019 Constantine N. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution Licence](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.



**Niel T. Constantine**

Institute of Human Virology and Department of Pathology, University of Maryland School of Medicine, Baltimore, MD, USA

**General:** The paper is well-written and of importance for scientists in the diagnostics arena. The effort is noteworthy, and the challenges of such a repository are evident. The authors are experts in the field. A few comments for improvement are indicated below.

**Abstract:**

1. The authors indicate 31,000 plasma specimens, but in the Review of the CEPHIA Repository section, they state 3,383 individuals with 13,856 different time points. The repository number and type of specimens are a little unclear, and perhaps the number and characteristics of the population of samples could be further clarified in one section.

2. The authors state "...other body fluids...". This is not described in subsequent sections and should be further explained.
3. The abstract mentions "support biomarker discovery". This should be further explained in a subsequent section.

**Table 2:**

- For the cost of the repository, the expenses could include more detail. For example, the database management is \$315,000: what exactly does this involve? Also, specimen maintenance is \$396,091: what does this entail? Are these costs per year?

**Box 1:**

- Ethics: what is meant by ethical requirements?
- Ownership: how is it determined who should receive valuable specimens?

**Page 6:**

- EDDI method: not well defined or explained.
- Critical Features: the authors do not indicate the number of serial samples or number of seroconversion panels. Perhaps this should be stated with the total number of samples and time points (as stated in the Abstract).

**Figure 1:**

- The authors mention whole blood and PBMCs. How would these be processed and stored for use, and how would they be used by users?

**Discussion:**

- "expensive white elephant" - what does this mean? I would suggest not to use this phrase; many readers would not understand what this means. Also, how would it be determined if projects are "going to be valuable"?

**Data Availability:**

- Should be corrected to: "No data are associated..."

**Number 2 question above:**

- The authors could add statements on the opinions of others as to the value for the repository and any differing views or discussions by others.

**Is the rationale for the Open Letter provided in sufficient detail?**

Yes

**Does the article adequately reference differing views and opinions?**

Partly

**Are all factual statements correct, and are statements and arguments made adequately supported by citations?**

Yes

**Is the Open Letter written in accessible language?**

Yes

**Where applicable, are recommendations and next steps explained clearly for others to follow?**

Yes

**Competing Interests:** No competing interests were disclosed.

**Reviewer Expertise:** Diagnostics, quality assurance, Immunology

**I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.**

Reviewer Report 08 August 2019

<https://doi.org/10.21956/gatesopenres.14170.r27582>

© 2019 Cloherty G. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution Licence](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.



**Gavin A. Cloherty**

Infectious Disease Research, Diagnostics Division, Abbott Laboratories, Chicago, IL, USA

The letter clearly describes the history of the CEPHIA repository.

This letter is valuable in that it describes the hurdles faced by any organization trying to establish a sample repository for research purposes and makes recommendations for how those hurdles might be overcome.

The authors do a very good job describing the value (often unrecognized or difficult to quantify) of such a repository. They also accurately describe the challenges facing diagnostic manufacturers, diagnostic laboratories and physicians caused by novel approaches to HIV care.

**Is the rationale for the Open Letter provided in sufficient detail?**

Yes

**Does the article adequately reference differing views and opinions?**

Yes

**Are all factual statements correct, and are statements and arguments made adequately supported by citations?**

Yes

**Is the Open Letter written in accessible language?**

Yes

**Where applicable, are recommendations and next steps explained clearly for others to follow?**

Yes

***Competing Interests:*** No competing interests were disclosed.

***Reviewer Expertise:*** Infectious Disease Diagnostics

**I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.**

---